Treatment of pediatric acute lymphoblastic leukemia

Research output: Contribution to journalArticle

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3years. Treatment intensity based on risk-based stratification is the cornerstone of treatment. Patients with features of more favorable disease are spared the more toxic effects of chemotherapy, whereas more aggressive regimens are reserved for those with higher-risk disease. Prognosis of relapsed pediatric ALL depends primarily on duration of remission and site of relapse.

Original languageEnglish (US)
Pages (from-to)61-73
Number of pages13
JournalPediatric Clinics of North America
Volume62
Issue number1
DOIs
StatePublished - Feb 1 2015

    Fingerprint

Keywords

  • Acute lymphoblastic leukemia
  • Leukemia treatment
  • Risk-based stratification

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this